HepaGam B (Cangene bioPharma Inc.)
Welcome to the PulseAid listing for the HepaGam B drug offered from Cangene bioPharma Inc.. This Human Immunoglobulin [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
| LABELER NAME / MANUFACTURER: | Cangene bioPharma Inc. |
| NON-PROPRIETARY NAME: | Hepatitis B Immune Globulin (Human) |
| SUBSTANCE NAME: | HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN |
| TYPE: | PLASMA DERIVATIVE |
| PHARMA CLASS: | Human Immunoglobulin [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] |
| ROUTE: | INTRAMUSCULAR; INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2010-08-01 |
| END MARKETING DATE: | 0000-00-00 |
HepaGam B PLASMA DERIVATIVE Details:
| Item Description | HepaGam B from Cangene bioPharma Inc. |
| LABELER NAME: | Cangene bioPharma Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 312([iU]/mL) |
| START MARKETING DATE: | 2010-08-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 53270-0051_148e1fa7-efc7-47be-a20a-1e9a623852e2 |
| PRODUCT NDC: | 53270-0051 |
| APPLICATION NUMBER: | BLA125035 |
Other HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:
